The identification of antigens with the capacity to induce a broad spectrum of protective immunity is an important consideration in the design of a Lyme disease vaccine. In this study, the range of protection provided by outer surface protein (Osp) A or OspC vaccination was compared. Mice actively immunized with OspA or OspC were challenged with 3 North American isolates of Borrelia burgdorferi. OspA-immunized mice were fully protected from infection with each of the isolates, whereas mice immunized with OspC were protected from infection with the homologous isolate but not with 2 heterologous isolates. Sequence analysis revealed that the ospA genes from these 3 isolates were >99% homologous, whereas the ospC genes shared only 81%-85% homology. Western blot analysis suggested antigenic heterogeneity associated with OspC but not OspA.These results indicate that genetic and antigenic heterogeneity may limit the usefulness of OspC as a vaccine constituent.
Lyme disease is the most prevalent vectorbome disease in North America [1] . The causative agent of Lyme disease, Borrelia burgdorferi sensu lato, is a pathogenic spirochete that can be transmitted by the bite of ticks belonging to the Ixodes genus. Genetic analysis has revealed at least 3 genospecies of B. burgdorferi sensu lato, including B. burgdorferi sensu stricto, B. garinii, and B. afzelii [2] . Most isolates from North America have been grouped into the B. burgdorferi sensu stricto genospecies [2] . Transmission of B. burgdorferi may lead to a multisystem disease that can include skin, joint, cardiac, and neurologic involvement. While Lyme disease is often treatable with antibiotics early in the course of the disease, patients with chronic Lyme disease are sometimes refractory to treatment, and in rare instances, the infection persists despite prolonged antibiotic intervention [3] . Consequently, considerable effort is underway to develop an effective vaccine for the prevention of Lyme disease in humans and other animals [4] .
Antibodies produced in response to vaccination with B. burgdorferi organisms have proved effective in preventing infection of laboratory animals with B. burgdorferi [5, 6] . These observations have led to development of a commercially available bacterin for use in canines [7] . While this bacterin is safe and effective, protective immunity appears to be of short duration and limited in range [8] . Moreover, the potential for the induction of an autoimmune response has shifted the focus from a whole cell vaccine to a subunit vaccine approach [9, 10] .
Several B. burgdorferi antigens that elicit a protective immune response in laboratory animals are under consideration as vaccine candidates [11-16J. Of these antigens, outer surface protein (Osp) A, OspB, and OspC are expressed in the greatest amounts in cultured organisms and consequently are the most characterized. The genes encoding OspA and OspB comprise an operon located on a 49-kbp linear plasmid [17] , whereas the ospC gene is located on a 26-to 27-kbp circular plasmid [18, 19] . Considerable genetic and antigenic heterogeneity has been described for OspA, OspB, and OspC among B. burgdorferi sensu lato [20] . However, OspA and OspB of North American isolates of B. burgdorferi (genospecies sensu stricto) are relatively well conserved. Wilske et al. [21] described a single OspA serotype and genotype for North America B. burgdorferi isolates. In contrast to OspA, OspC appears to be more genetically and antigenically heterogeneous [22] [23] [24] [25] . With the use of restriction enzyme length polymorphism analysis, Livey et al. [23] described 33 distinct ospC variants, 11 of which were found among North American B. burgdorferi isolates. While OspA vaccination has been broadly effective in preventing infection of laboratory animals with North American B. burgdorferi [26] [27] [28] [29] , the range of protection induced by OspC vaccination has not been addressed.
In this study, we compared the ability of OspA and OspC antigens derived from B. burgdorferi SON188 (sensu stricto) to prevent infection of C3H mice challenged with either the homologous or 2 heterologous North American B. burgdorferi isolates. Sequencing of the ospA gene and ospC gene from each isolate was also done to evaluate the relationship of sequence relatedness to vaccine performance.
Materials and Methods
Organisms. SON188, CA4, and 297 have been designated B. burgdorferi genospecies sensu stricto [30, 31] . SON188 and CA4
were isolated from Ixodes pacificus, whereas 297 was derived from human cerebrospinal fluid. The isolates were passaged in mice to assess infectivity, and we determined the ID so of the reisolates as described by Barthold [32] . The m., of SON188, CA4, and 297 for subcutaneous inoculation were 3 X 10 4 , 3 X 10 3 , and 500 spirochetes, respectively. For all experiments, the isolates were maintained for fewer than five passages in Barbour-Stoenner-Kelly medium (BSK II).
Recombinant antigens. The recombinant fusion proteins used in this study have been described [33] . Briefly, the ospA and ospC genes ofSON188 were cloned individually into the pMal c2 vector (New England Biolabs, Beverly, MA) and expressed in Escherichia coli as proteins fused to the carboxy-terminal end of maltose-binding protein. The leader sequence and the codon encoding the N-terminalcysteine of the ospA and ospC genes were omitted from these constructs. Thus, these constructs would be expected to express an unlipidated form of the predicted mature OspA and OspC protein.
Without insert, the pMal c2 vector encodes a fusion protein consisting of a portion of ,a-galactosidase (,a-gal) fused to the Cterminal end of maltose-binding protein. This recombinant fusion protein was used as a negative control in later experiments. Expression of the 3 recombinant fusion proteins (,a-gal, OspA, and OspC) was followed by purification of the antigens by amylose affinity chromatography (New England Biolabs) according to manufacturer's instructions.
Protection studies. C3H1HeN mice (3-4 weeks old) were immunized with ,a-gal, OspA, or Ospt,'. Each mouse received by intraperitoneal administration 10 mg of antigen emulsified 1:1 (voll vol) in Freund's adjuvant. Mice were initially primed with antigen in complete Freund's adjuvant. This was followed by two boosts with antigen emulsified with incomplete Freund's adjuvant on days 14 and 35. On day 42 after the primary immunization, serum samples were collected and pooled by immunogen group. Ten days after the final boost, mice from each immunogen group were challenged with SON188, CA4, or 297. Each mouse received by subcutaneous injection a dose corresponding to 30X ID so . Twentyone days later the mice were sacrificed, and selected tissues (ear punch biopsy, bladder, and right inguinal lymph node) were inoculated into BSK II. Cultures were monitored for the presence of spirochetes by darkfield microscopy for 21 days.
Western blotting. Spirochetes were washed with PBS supplemented with 5 mM MgCh, quantitated by the Bradford protein assay, and lysed in SDS-PAGE sample buffer. Five micrograms of total protein was loaded into each well of a 12% acrylamide gel, and the proteins were separated by electrophoresis at 150 V for 1 h. The proteins were transferred to a nitrocellulose membrane using a semidry blotting apparatus (LKB, Bromma, Sweden). The nitrocellulose membrane was blocked in Blotto (50 mMTRIS, 150 mM NaCI, 0.05% Tween 20, and 5% nonfat dry milk [pH 7.5]) and probed with a 1:20,000 dilution of anti-OspA serum or a 1:2000 dilution of anti-OspC serum in Blotto. These sera were derived from the mice described in the protection study (above). The nitrocellulose membrane was then washed with TRIS-buffered saline supplemented with 0.05% Tween 20 (TTBS), and the bound antibodies were detected with a 1:5000 dilution of alkaline phosphatase-labeled goat anti-mouse IgG (Kirkegaard & Perry Laboratories, Gaithersburg, MD) in Blotto. After a final wash with TTBS, the membrane was developed in a solution of bromochloroindolyl phosphate-nitroblue tetrazolium. DNA sequencing. For sequencing the SON188 ospA and ospC genes, the pMal c2 constructs [33] were used as template DNA. The plasmid DNA was isolated and purified for DNA sequencing using a plasmid system (Midi; Qiagen, Chatsworth, CA). The ospA sequences of CA4 and 297 and the ospC sequence of CA4 were derived from polymerase chain reaction (PCR) products. PCR amplification of the ospA and ospC genes by PCR was done as described [33] . The PCR products were purified for DNA sequencing using a spin PCR purification kit (QIAquick; Qiagen). DNA sequencing was done using the DyeDeoxy termination cycle sequencing method (Perkin-Elmer, Norwalk, CT) according to manufacturer's recommendations. The sequencing reactions were analyzed with an automated DNA sequencer (model 377; Applied Biosystems, Foster City, CA). Nucleotide sequence was determined from both strands and at least twice for each gene. Sequence relatedness was analyzed using the MacDNAsis software package (Hitachi Software Engineering America, San Bruno, CA). The ospC gene sequence of297 was obtained from GenBank (accession no. U08284) [34] .
Results
Protection study. Table I shows results of the mouse protection study. All mice immunized with OspA derived from SONl88 and challenged with SONI88, CA4, or 297 were protected from infection, whereas mice receiving the ,a-gal immunogen (negative control) were infected with all 3 isolates. OspC immunization, however, provided protection only in mice challenged with the homologous isolate SONI88. All but I mouse in the OspC immunogen group were protected from SONl88 challenge (P < .025, X 2 ) . In contrast, none of the mice immunized with OspC and challenged with either heterologous isolate CA4 or 297 were protected from infection.
Western blot analysis. Lysates of SONI88, CA4, and 297 were separated by SDS-PAGE, transferred to a nitrocellulose Discussion 77% homologous. The CA4 and 297 OspC amino acid sequences shared 74% and 76% sequence identity, respectively, with the OspC amino acid sequence of SON188. Similarly, only 77% sequence identity was shared between the CA4 and 297 OspC amino acid sequences. Probert membrane, and probed with anti-OspA (SON188) or anti-OspC (SON188) sera. The antisera were derived from mice described in the protection study and were collected prior to spirochete challenge. The anti-OspA serum reacted strongly with a 31-kDa band present in all 3 spirochetal lysates (figure 1). In contrast, OspC immunostaining of the 3 isolates produced bands of varying intensity and molecular mass (figure 1). The anti-OspC serum reacted strongly with a 22-kDa band present in the SON188 lysate. This serum also recognized a 23-kDa band present in both the CA4 and 297 lysates, but the intensity of immunostaining was only moderate for the CA4 lysate and faint for the 297 lysate.
Sequence analysis. The SON188, CA4, and 297 ospA genes and the SON188 and CA4 ospC genes were sequenced and assigned the following GenBank accession numbers: L8ll28, L8ll32, L8ll29, L8l130, and L8l132, respectively. The 297 ospC gene sequence described by Fung et al. [34] was obtained from GenBank (accession no. U08284). The portion of the ospA genes predicted to encode the mature proteins was aligned (data not shown) and the degree of sequence relatedness determined. The ospC genes were similarly compared. The degree of sequence identity displayed among the ospA genes ofSON188, CA4, and 297 was >99%, whereas sequence identity among the ospC genes was 81%-85%.
The deduced amino acid sequences (less the leader peptide and N-terminal cysteine) from the ospA and ospC genes of SON188, CA4, and 297 were aligned for comparison and are shown in figure 2 . The ospA gene of all 3 isolates was predicted to encode a mature protein of 257 aa. Comparison of the predicted OspA amino acid sequences for identity revealed >99% homology among the 3 isolates. The lengths of the ospC gene products of SON188 and CA4 were 190 and 191 aa, respectively. The partial 297 OspC amino acid sequence determined by Fung et al. [34] would encode a protein of~191 residues. In contrast to the high degree of sequence relatedness observed for OspA, the OspC amino acid sequences were only 74%-This study compared the ability of OspA and OspC vaccination to provide protective immunity in mice challenged with 3 North American B. burgdorferi isolates. Immunization of mice with OspA provided cross-protective immunity, whereas immunization with OspC protected mice challenged with the homologous B. burgdorferi isolate but failed to prevent infection of mice challenged with heterologous isolates. These results confirm and extend those of an earlier study in which immunization of mice with OspA, OspB, or OspC prevented infection of mice challenged with the homologous B. burgdorferi isolate SONl88 [33] .
Several studies have documented the ability of OspA or OspB immunization to induce a protective immune response [12, 13, 16] . OspA-or OspB-specific antibodies can kill or inhibit the growth of B. burgdorferi in vitro [35] [36] [37] . Although the mechanism of in vitro killing of B. burgdorferi by antibodies is unclear, some antibodies are directly borreliacidal and function independently of complement or effector cells [37] . Lovrich et al. [36] utilized an in vitro borreliacidal assay to identify 6 OspA seroprotection groups among B. burgdorferi sensu lato. All but 1 of the North American isolates evaluated by these investigators could be grouped into a single seroprotection group. These results are consistent with those of serologic and genetic studies demonstrating a single predominant OspA serotype/genotype in North America [21] . Moreover, these in vitro observations also correlate well with in vivo protection studies [36] .
Vaccination of laboratory animals with either OspA or OspB or both (OspA/B) has proven efficacious in preventing infection by B. burgdorferi belonging to the same genotype, but not by organisms belonging to a different genotype [38] . The ability of OspA/B vaccination to prevent infection of mice or dogs challenged with infected ticks collected from regions in which the organism is endemic supports the notion of a single dominant OspA/B seroprotective group in North America [26] [27] [28] [29] . However, minor seroprotective groups may also exist. Indeed, a second North American OspA/B seroprotective group has been identified by in vitro and in vivo protection studies and may correspond to the recently delineated DN127 genogroup [30, 36, 39] . Taken together, these studies indicate that North American isolates of B. burgdorferi are relatively homogeneous with regard to OspA/B serotype/genotype and suggest that a subunit vaccine consisting of a limited number of OspA/B antigens may be efficacious. Although limited in scope, our results with OspA vaccination also support this view. . . . . . . . . . . F . . . . . • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . • . . . . . . . . . . . The discovery of B. burgdorferi that express truncated forms of OspNB or lack OspNB expression altogether has prompted the search for additional antigens that may broaden the efficacy of a subunit vaccine [15, 35, [40] [41] [42] [43] [44] . OspC has warranted further consideration as a vaccine constituent by virtue of its ability to completely protect laboratory animals from syringe or tick challenge with the homologous B. burgdorferi isolate [15, 33, 45] .
The ospC gene has been localized to a 26-to 27-kbp circular plasmid and encodes a 22-kDa surface-exposed lipoprotein [18, 19, 46] . In contrast to OspA, several reports have described a much higher degree of OspC sequence and antigenic heterogeneity among North American isolates of B. burgdorferi [22] [23] [24] [25] 34, [47] [48] [49] [50] . Livey et al. [23] described 11 ospC genotypes among a panel of 15 North American isolates. Jauris-Heipke et al. [22] screened a small panel of North American B. burgdorferi isolates and demonstrated 5 distinct ospC genotypes among a single OspA serotype/genotype. Similarly, we found that SONI88, CA4, and 297 share significant ospA sequence identity, whereas the ospC gene sequences were notably dissimilar. Thus, while all 3 isolates can be grouped into a single ospA genotype, the considerable ospC heterogeneity suggests 3 distinct ospC genotypes.
The ospC genotypic differences among the isolates tested in this study were also manifested at the antigenic level. Reactivity of the anti-OspC (SONI88) serum with the SONI88, CA4, and 297 lysates was of strong, intermediate, and weak intensity, respectively. The weak reactivity observed with 297 was not simply due to decreased OspC expression, since anti-OspC (297) serum reacts strongly with this isolate (unpublished data) [42] . OspC antigenic heterogeneity was further evident by the failure of OspC (SONI88) immunization to protect against challenge with CA4 or 297. In contrast, OspA vaccination prevented infection of mice with all 3 isolates. Our results with OspA vaccination complement an earlier study in which passive immunization of lID 1997; 175 (February) mice with anti-OspB (SON188) serum prevented infection with SON188, CA4, and 297 [51] .
The results of our study suggest that prophylaxis induced by OspC vaccination may be limited in range relative to that of OspA/B vaccination. The lack of efficacy associated with OspC vaccination appears to be due to the extensive OspC heterogeneity found among B. burgdorferi sensu lato. As was determined for the isolates described in this report, OspC may display a high degree of heterogeneity within an individual genospecies or among isolates derived from similar geographic regions [22, 23] . Much of the OspC heterogeneity maps to a central hypervariable region (aa 75-192) [22, 23, 49] . Theisen et al. [49] have suggested that this region may be highly antigenic and thatOspC heterogeneity in the region may be due to immunologic pressures.
OspC, unlike OspA/B, elicits an early and persistent serologic response throughout the first year of B. burgdorferi infection in humans [34, 52] . In our hands, hyperimmune anti-OspC serum possesses only low levels ofborreliacidal activity against the homologous isolate [33] and did not protect mice in passive immunization studies (unpublished data). Conceivably, persistent exposure of B. burgdorferi to suboptimal levels of neutralizing OspC antibodies may over time select for subpopulations expressing variant OspC molecules. OspC sequence analyses have suggested that such variants may arise through lateral gene exchange and recombinational events [22, 23] . Thus, the higher degree of OspC diversity may be a consequence of intragenic recombination and the subsequent immunologic selection of these OspC variants.
In summary, we found that immunization with OspA, but not OspC, protects mice from infection with 2 heterologous North American B. burgdorferi isolates. Both immunogens, however, prevented infection of mice with the homologous isolate. Sequence analysis revealed that the isolates could be grouped into a single ospA genotype and 3 distinct ospC genotypes. Therefore, the success of OspA vaccination was attributed to OspA homogeneity, whereas the failure of OspC vaccination was likely a result of OspC heterogeneity. These results suggest that the extensive OspC heterogeneity exhibited by B. burgdorferi may limit the effectiveness of OspC as a vaccine constituent.
